{"entity":{"id":"nct05664243","kind":"trial","name":"A Phase 1b / 2 Drug Resistant Immunotherapy With Activated, Gene Modified Allogeneic or Autologous γδ T Cells (DeltEx) in Combination With Maintenance Temozolomide in Subjects With Recurrent or Newly Diagnosed Glioblastoma","aka":[],"tldr":"A phase 1/2 trial of Autologous genetically modified gamma-delta T cells in glioma & glioblastoma, run by In8bio Inc., active and no longer recruiting.","summary":"A Phase 1b / 2 Drug Resistant Immunotherapy With Activated, Gene Modified Allogeneic or Autologous γδ T Cells (DeltEx) in Combination With Maintenance Temozolomide in Subjects With Recurrent or Newly Diagnosed Glioblastoma is a phase 1/2 interventional study registered as NCT05664243 by In8bio Inc., with 4 participants enrolled, started 2023-09-08 and due to reach its primary completion in 2025-12. Interventions recorded: Autologous genetically modified gamma-delta T cells and Allogeneic genetically modified gamma-delta T cells.","status":"active","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT05664243","url":"https://clinicaltrials.gov/study/NCT05664243"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["glioblastoma"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT05664243","phase":"1/2","setting":"A Phase 1b / 2 Open-label Study to Investigate the Safety, Tolerance and Efficacy of Drug Resistant Immunotherapy (DRI) With Activated, Gene Modified Allogeneic or Autologous γδ T Cells (DeltEx) in Combination With Maintenance Temozolomide (TMZ) in Subjects With Recurrent or Newly Diagnosed Glioblastoma","sponsor":"In8bio Inc.","enrolled":4,"outcomes":[]},"route":"/trials/nct05664243/","neighbours":{"cancer":[{"id":"glioblastoma","kind":"cancer","name":"Glioma & glioblastoma","route":"/cancers/glioblastoma/"}]}}